The mega-project cost Richter up to EUR 50 million.Continue reading
Drug candidates are identified using state-of-the-art screening assays against clinically validated biological targets.
“BCI has applied its expertise in kinase research to identify highly valuable preclinical candidates,” noted Dr. Péter Turek, Head of Richter Women’s Healthcare (WHC). “This acquisition is a perfect strategic fit with our recently announced earlier deal, as it helps to frame our initial research expansion in the WHC territory located in Liège.”
BCI Pharma was founded in March 2013 by Dominique Surleraux and Dr Elisabeth Picou. Backed by molecular modelling, the company designed and developed novel molecules/compounds that can inhibit target kinases with very high selectivity, thereby improving the safety and tolerability profile of patients.
Gedeon Richter Plc., based in Budapest, Hungary, is a major pharmaceutical company in Central and Eastern Europe with a growing direct presence in Western Europe, China, Latin America and Australia. Having reached a market capitalization of EUR 4.3 billion by the end of 2023, Richter’s consolidated sales for the same year were around EUR 2.1 billion.
Richter’s product portfolio covers several important therapeutic areas, including women’s health, central nervous system and cardiovascular.
With the largest research & development (R&D) unit in Central and Eastern Europe, Richter’s original research focuses on central nervous system disorders. With its widely recognized expertise in steroid chemistry, Richter is a major player in Women’s Health worldwide.
Via Richter Gedeon; Featured image via Hungary Today
